Oxidative Functionalization of Alcohols and Aldehydes via the Merger of Oxoammonium Cations and Photoredox Catalysis

Jyoti Nandi,[†] John M. Ovian,[†] Christopher B. Kelly,[†] and Nicholas E. Leadbeater *,[†]

[†]Department of Chemistry, University of Connecticut, 55 N. Eagleville Road, Storrs, Connecticut 06269, USA

Supporting Information

Key to Abbreviated Terms	S1
General Considerations Comments regarding origins of commercially-available starting materials, purification of solvents, and spectroscopic techniques. Details regarding the design of LED-based photoreactors.	S1
Optimization & Control Studies for Photoredox Oxidative Amidation Procedures for control and optimization experiments as well as a plausible mechanistic rationale for observed oxidative amidation products in the absence of a TEMPO-based species.	S 3
Representative Procedure for Oxidative Amidation from Aldehydes General procedure for synthesis, isolation procedures, and spectral characterization information for <i>N</i> -acyl azoles.	S 6
One Pot Procedure for Photoredox Oxidative Amidation from Alcohols General procedure, isolation procedures, and spectral characterization for the conversion of an alcohol to an <i>N</i> -acyl pyrazole via a one-pot protocol.	S13
Sequential Reactions of N-Acyl Pyrazoles Procedures for tandem photoredox oxidative amidation and transamidation from alcohols and aldehydes along with spectral characterization information for the resulting amides.	S17
¹ H NMR Spectra of Synthesized Compounds	S19
¹³ C NMR Spectra of Synthesized Compounds	S51
¹⁹ F NMR Spectra of Synthesized Compounds	S82

Key to Abbreviated Terms:

4CzIPN – 2,4,5,6-Tetra(9H-carbazol-9-yl)isophthalonitrile	TEMPO – 2,2,6,6-tetramethylpiperidine 1-oxyl
ACT – 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl	TEMPOH –2,2,6,6-tetramethylpiperidin-1-ol
bpy – 2,2'-Bipyridyl	THF – Tetrahydrofuran
CDCl ₃ – Deuterated chloroform	TLC – Thin layer chromatography
DMSO- <i>d</i> ₆ – Deuterated dimethylsulfoxide	
Et ₂ O – Diethyl ether	
EtOAc – Ethyl acetate	
Hex – Hexanes	
LED – Light-emitting diode	

 $MesAcr^{+}BF_{4}{}^{+}-9{\text -}Mesityl{-}10{\text -}methylacridinium tetrafluoroborate}$

General Considerations:

General: All chemical transformations requiring inert atmospheric conditions or vacuum distillation utilized Schlenk line techniques with a 3- or 4-port dual-bank manifold. Nitrogen was used to provide such an atmosphere. NMR Spectra (¹H, ¹³C, ¹⁹F) were performed at 300 K on either a Brüker Avance Ultra Shield 300 MHz NMR, Brüker DRX-400 400 MHz NMR, or Brüker Avance 500 MHz NMR. ¹H NMR spectra were referenced to residual non-deuterated chloroform (7.26 ppm) in CDCl₃. ¹³C NMR spectra were referenced to CDCl₃ (77.30 ppm). ¹⁹F NMR spectra were referenced to hexafluorobenzene (-164.9 ppm).¹ High-resolution mass spectra were performed on a JEOL AccuTOF-DART SVP 100 in positive direct analysis in real time (DART) ionization method, using PEG as the internal standard. Reactions were monitored by an Agilent Technologies 7820A Gas Chromatograph attached to a 5975 Mass Spectrometer, ¹H NMR, and/or by TLC on silica gel plates (60Å porosity, 250 µm thickness). TLC analysis was performed using hexanes/ethyl acetate as the eluent and visualized using permanganate stain, *p*-anisaldehyde stain, Seebach's Stain, and/or UV light. Flash chromatography and silica plugs utilized Dynamic Adsorbents Inc. Flash Silica Gel (60Å porosity, 32-63 µm).

Chemicals: Deuterated chloroform (CDCl₃) was purchased from Cambridge Isotope Laboratories and stored over 4Å molecular sieves and K₂CO₃. Deuterated DMSO- d_6 was used as purchased. Na₂SO₄, CH₂Cl₂, EtOAc, hexane, pentane, Et₂O, THF, MeCN, acetone, pyridine, Na₂S₂O₈ and 2,6-lutidine were purchased from Sigma-Aldrich. Molecular sieves for photochemical experiments (3Å molecular sieves, 3.2 mm pellets) were also purchased from Sigma-Aldrich. Hexafluorobenzene was purchased from Synquest Laboratories and/or Oakwood Chemicals. Aldehydes and alcohols were either purchased from commercial suppliers (and distilled/recrystallized before use), or prepared in-house. All azoles were purchased from commercial suppliers and used without further purification. The oxoammonium salt 4-acetamido-2,2,6,6-tetramethyl-1-oxopiperidin-1-ium ("Bobbitt's Salt") and 4-acetamido-TEMPO (ACT) was prepared according to our recently published protocol.² TEMPOH was purchased from Synthonix. The photocatalysts Ru(bpy)₃(PF₆)₂ and 4CzIPN were prepared in-house by literature procedures^{3,4}

Photochemistry: Irradiation of reaction vessels was accomplished using blue LEDs. LEDs were configured as outlined in the *Photochemical Reactor Design* section of previous articles.⁵ A fan was employed to ensure reactions remained at or near rt when using LEDs.

Information for LED-based Photoreactor Components:

- *Blue LEDs*: 39.4 inch strips, 470 nm blue light, 32918 mcd ft⁻¹
- Power Supply: 12V DC power supply 60 Watt
- *Connectors*: LC2 Locking male connector CPS adapter cable
- *Clip Fan*: 2-Speed clip fan, 6-inch
- Pyrex crystallizing dishes (150 × 75 mm)
- Aluminum foil, duct tape

¹ Ravikumar, I.; Saha, S.; Ghosh, P. Chem. Commun. 2011, 47, 4721.

² Mercadante, M. A.; Kelly, C. B.; Bobbitt, J. M.; Tilley, L. J.; Leadbeater, N. E. Nat. Protoc. 2013, 8, 666.

³ Kelly, C. B.; Patel, N. R.; Primer, D. N.; Jouffroy, M.; Tellis, J. C.; Molander, G. A. Nat. Protoc. 2017, 12, 472.

⁴ Patel, N. P.; Kelly, C. B.; Siegenfeld, A. P.; Molander, G. A. ACS Catal. 2017, 7, 1766.

⁵ For information on these reactors and their construction see the supporting information of: (a) Patel, N. R.; Kelly, C. B.; Jouffroy, M.; Molander, G. A. *Org. Lett.* **2016**, *18*, 764. (b) Jouffroy, M.; Kelly, C. B.; Molander, G. *Org. Lett.* **2016**, *18*, 764. (b) Jouffroy, M.; Kelly, C. B.; Molander, G. *Org. Lett.* **2016**, *18*, 876.

Optimization & Control Studies for Photoredox Oxidative Amidation

Procedure for optimization and control studies:

To a 1 mL reaction vial equipped with a stir bar was added *p*-tolualdehyde **4a** (0.060 g, 0.0005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole **5a** (0.051 g, 0.00075 mol, 1.5 equiv), pyridine (0.099 g, 0.1 mL, 0.00125 mol, 2.5 equiv), and the appropriate solvent. The solution was allowed to stir at room temperature for two minutes. After this time, the vial was charged with appropriate photocatalyst and Na₂S₂O₈ (0.261 g, 0.0011 mol, 2.2 equiv). The vial was sealed with a cap and was irradiated in the aforementioned LED reactor for 18 h. The temperature of the reaction was maintained at approximately 27 °C *via* a fan. Conversion was evaluated by both GCMS and ¹H NMR of the crude reaction mixture.

	4a +	ACT (x mol% Photocatalyst (x m Na ₂ S ₂ O ₈ (2.2 eq pyridine (2.5 equ Solvent, Blue LEDs, n) hol%) uiv) iv) t, 18 h	×>
Entry	Solvent (Conc. of 4a)	Photocatalyst (mol%)	ACT loading (mol%)	Conversion to 6a (%)
1^b	MeCN (0.5 M)	$Ru(bpy)_3(PF_6)_2(2.5 mol\%)$	10	0
2	MeCN (0.5 M)	$Ru(bpy)_3(PF_6)_2(2.5 mol\%)$	10	98
3	THF (0.5 M)	$Ru(bpy)_3(PF_6)_2(2.5 mol\%)$	10	20
4	EtOAc (0.5 M)	$Ru(bpy)_3(PF_6)_2(2.5 mol\%)$	10	57
5	CH ₂ Cl ₂ (0.5 M)	$Ru(bpy)_3(PF_6)_2(2.5 mol\%)$	10	50
6	'BuOH (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2.5 mol%)	10	59
7	TFE (0.5 M) (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2.5 mol%)	10	< 5
8	DMSO (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2.5 mol%)	10	0
9	DMF (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2.5 mol%)	10	61
10	Acetone (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2.5 mol%)	10	85
11	MeCN (0.5 M)	MesAcr+ClO ₄ - (2 mol%)	10	trace
12	MeCN (0.5 M)	4CzIPN (2.5 mol%)	10	0
13	MeCN (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (1.5 mol%)	10	90
14	MeCN (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2 mol%)	10	98
15	MeCN (0.25 M)	$Ru(bpy)_3(PF_6)_2(2 mol\%)$	10	46
16	MeCN (0.1 M)	$Ru(bpy)_3(PF_6)_2(2 mol\%)$	10	26
17	MeCN (0.5 M)	Ru(bpy) ₃ (PF ₆) ₂ (2 mol%)	20	100
18^{c}	MeCN (0.5 M)	$Ru(bpy)_3(PF_6)_2(2 mol\%)$	0	99
19^{d}	MeCN (0.5 M)	$Ru(bpy)_3(PF_6)_2(2 mol\%)$	0	85

Table S1: Optimization of the ACT/Photoredox Dual Catalytic Process

^{*a*} Percent conversion was approximated based upon relative areas from the GCMS trace of a given run and confirmed by ¹H NMR. In cases where the two values differed substantially, ¹H NMR integrations were used. Conversion = 100 × (area of oxidative amidation product **6a**)/(area of **6a** + area of **4a**). ^{*b*} No Na₂S₂O₈ added and reaction performed under O₂ ^{*c*} 20 mol% Bobbitt's salt used in place of ACT. ^{*d*} 20 mol% TEMPOH used in place of ACT.

Table S2: Control Studies for the ACT/Photoredox Dual Catalytic Process



Entry	Deviation from procedure	Conversion to 6a (%)
1	None	>99
2	<i>No Ru(bpy)</i> ₃ (<i>PF</i> ₆) ₂	0
3	No light	0
4	No ACT	52^b
6	No Na2S2O8	0

^{*a*} Percent conversion was approximated based upon relative areas from the GCMS trace of a given run and confirmed by ¹H NMR. In cases where the two values differed substantially, ¹H NMR integrations were used. Conversion = 100 × (area of oxidative amidation product **6a**)/(area of **6a** + area of **4a**). ^{*b*} ~10% carboxylic acid formation along with several unidentifiable products

Procedure for "light/dark" studies:

To a 20-mL vial equipped with a stir bar was added *p*-fluorobenzaldehyde (0.620 g, 0.005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole (0.511 g, 0.0075 mol, 1.5 equiv), pyridine (0.989 g, 1.0 mL 0.0125 mol, 2.2 equiv), and MeCN (10 mL, 0.5 M). The reaction mixture was was stirred for about two minutes at room temperature. After this time, Na₂S₂O₈ (2.618 g, 0.011 mol, 2.2 equiv) and the photocatalyst Ru(bpy)₃(PF₆)₂ (0.086 g, 0.0001 mol, 0.02 equiv) were added. After the addition of the components, an aliquot was taken and kept in the dark until a ¹⁹F NMR was obtained (T₀ data point). The remainder of the reaction mixture was sealed in the vial and irradiated in the aforementioned LED reactor for 30 minutes. After this time, an aliquot was taken and kept in the dark until a ¹⁹F NMR was obtained (T₁ data point). The reaction mixture was removed from the irradiation zone and placed on a stir plate in complete darkness (via the aid of aluminium foil and a box) for 30 minutes. After this time, the reaction was returned to the irradiation zone for an additional 240 minutes, at which time a final aliquot was take (T_∞ data point) By this time the reaction was essentially complete.

Table S3: Control Studies for the ACT/Photoredox Dual Catalytic Process



Entry	Time (min)	Conversion to 6c (%) ^a
1	0	0
2	30	13
3	60	14
4	300	97

^a Percent conversion determined by ¹⁹F NMR of the crude reaction mixture,

Figure S1: Plausible Mechanistic Rationale for Observed Oxidative Amidation in Absence of a TEMPO-based species



Representative Procedure for Photoredox Oxidative Amidation from Aldehydes



(1*H*-pyrazol-1-yl)(*p*-tolyl)methanone⁶ (6a)

To a 20-mL vial equipped with a stir bar was added *p*-tolualdehyde (0.601 g, 0.005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole (0.511 g, 0.0075 mol, 1.5 equiv), pyridine (0.989 g, 1.0 mL 0.0125 mol, 2.2 equiv), and MeCN (10 mL, 0.5 M). The reaction mixture was was stirred for about two minutes at room temperature. After this time, Na₂S₂O₈ (2.618 g, 0.011 mol, 2.2 equiv) and the photocatalyst Ru(bpy)₃(PF₆)₂ (0.086 g, 0.0001 mol, 0.02 equiv) were added. The vial was sealed with a cap and irradiated in the aforementioned LED reactor for 24 h. After this time, Et₂O (10 mL) was added and the resulting mixture was filtered through a coarse porosity fritted glass funnel. The solution was then transferred to a separatory funnel, diluted with Et₂O (50 mL) and 0.5 M aqueous HCl (75 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3×75 mL). The organic layers were then combined and washed with 0.5 M aqueous HCl (3×50 mL), saturated aqueous sodium bicarbonate (50 mL), deionized water (50 mL), and finally brine (100 mL). The organic layer was then dried over sodium sulfate and the solvent removed *in vacuo* to afford the pure *N*-acyl pyrazole (0.801 g, 86%).

¹H NMR (CDCl₃, 400 MHz) δ ppm 2.44 (s, 3 H) 6.51 (dd, *J*=2.75, 1.43 Hz, 1 H) 7.31 (d, *J*=8.14 Hz, 2 H) 7.79 (d, *J*=0.66 Hz, 1 H) 8.05 (d, *J*=8.14 Hz, 2 H) 8.43 (dd, *J*=2.86, 0.44 Hz, 1 H)
¹³C NMR (CDCl₃, 100 MHz) δ ppm 21.98 (CH₃) 109.50 (CH) 128.91 (C) 129.12 (CH 130.69 (CH) 131.95 (CH) 144.23 (C) 144.56 (CH) 166.57 (C)
GC-MS (EI) 186 ([M]⁺, 23%) 158 (13%) 119 (100%) 91 (50%) 65 (19%) 63 (6%)

(4-methoxyphenyl)(1H-pyrazol-1-yl)methanone,⁶ 6b (0.689 g, 68%) was prepared according to the



general procedure from *p*-anisaldehyde, **4b** (0.681 g, 0.005 mol) with the following modification: with the following modifications: 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction; 3) Further purification was accomplished by recrystallization from hexanes. The desired acyl

pyrazole, **6b**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.87 (s, 3 H) 6.49 (dd, *J*=2.64, 1.54 Hz, 1 H) 6.98 (d, *J*=9.02 Hz, 2 H) 7.78 (s, 1 H) 8.22 (d, *J*=9.02 Hz, 2 H) 8.42 (d, *J*=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 55.70 (CH₃) 109.18 (CH) 113.73 (CH) 123.70 (C) 130.73 (CH) 134.42 (CH) 144.29 (CH) 163.82 (C) 165.58 (C) **GC-MS** (EI) 202 ([M]⁺, 19%) 174 (6%) 135 (100%) 107 (10%) 92 (19%) 77 (23%) 64 (11%)

⁶ Ovian, J. M.; Kelly, C. B.; Pistritto, V. A.; Leadbeater, N. E. Org. Lett. 2017, 19, 1286.

(4-fluorophenyl)(1H-pyrazol-1-yl)methanone, 6c (0.868 g, 90%) was prepared according to the general



procedure from 4-fluorobenzaldehyde, **4c** (0.620 g, 0.005 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction. The desired acyl pyrazole, **6c**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.55 (dd, *J*=2.86, 1.32

Hz, 1 H) 7.20 (tt, *J*=8.60, 2.90 Hz, 2 H) 7.82 (d, *J*=0.66 Hz, 1 H) 8.15 - 8.32 (m, 2 H) 8.46 (d, *J*=2.42 Hz, 1 H) 13 C NMR (CDCl₃, 100 MHz) δ ppm 109.79 (CH) 115.67 (d, *J*_{C-C-F} =22.01 Hz, CH) 127.85 (d, *J*_{C-C-C} =3.12 Hz, C) 130.82 (CH) 134.77 (d, *J*_{C-C-F} =9.17 Hz, CH) 144.85 (CH) 165.99 (d, *J*_{C-F} =255.29 Hz, CF) 165.34 (s, C). 19 F NMR (CDCl₃, 377 MHz) δ ppm -107.95 – -107.82 (m, 1 F) GC-MS (EI) 190 ([M]⁺, 14%) 162 (12%) 123 (100%) 95 (70%) 75 (29%) 50 (7%) HRMS (DART) calcd for C₁₀H₈FN₂O [M+H]⁺: 191.0621, obs. 191.0609.

(1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone,⁶ 6d (1.01 g, 84%) was prepared according to



the general procedure from was prepared according to the general procedure from 4-(trifluoromethyl)benzaldehyde, **4d** (0.871 g, 0.005 mol) *with the following modification:* 5 equiv of pyridine (1.98 g, 0.025 mol) was used. The desired acyl pyrazole, **6d**, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.59 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.80 (d, *J*=8.14 Hz, 2 H) 7.84 (d, *J*=0.66 Hz, 1 H)

8.26 (d, J=8.14 Hz, 2 H) 8.49 (d, J=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.25 (CH) 123.80 (q, J_{C-F} =272.30 Hz, CF₃) 125.28 (q, J_{C-C-F} =3.60 Hz, CH) 130.59 (CH) 132.02 (CH) 134.48 (q, J_{C-C-F} =32.10 Hz, C) 135.08 (C) 145.22 (CH) 165.52 (C) ¹⁹F NMR (CDCl₃, 377 MHz) -114.53 (s, 3 F) GC-MS (EI) 240 ([M]⁺, 25%) 212 (13%) 173 (100%) 145 (89%) 125 (12%) 95 (14%) 75 (13%) 69 (5%) 50 (6%)

4-(1*H*-pyrazole-1-carbonyl)benzonitrile,⁶ 6e (0.872 g, 88%) was prepared according to the general procedure from 4procedure from was prepared according to the general procedure from 4formylbenzonitrile, 4e (0.656 g, 0.005 mol). The desired acyl pyrazole, 6e, was isolated as an powdery off-white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.57 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.77 - 7.83 (m, 3 H) 8.23 (d, *J*=8.58 Hz, 2 H) 8.45 (d, *J*=2.86 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.48 (CH) 116.47 (C) 118.08 (C)

130.61 (CH) 131.99 (CH) 132.16 (CH) 135.65 (C) 145.40 (CH) 165.03 (C) **GC-MS** (EI) 197 ([M]⁺, 21%) 169 (17%) 130 (100%) 102 (71%) 76 (13%) 75 (20%) 51 (11%).

methyl 4-(1*H*-pyrazole-1-carbonyl)benzoate,⁶ 6f (0.790 g, 69%) was prepared according to the general procedure from methyl 4-formylbenzoate, 4f (0.820 g, 0.005 mol). The desired acyl pyrazole, 6f, was isolated as a powdery off-white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.97 (s, 3 H) 6.56 (dd, J=2.86, 1.54 Hz, 1 H) 7.82 (d, J=0.66 Hz, 1 H) 8.17 (s, 4 H) 8.46 (d, J=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm

52.71 (CH₃) 110.11 (CH) 129.37 (CH) 130.57 (CH) 131.57 (CH) 133.93 (C) 135.60 (C) 145.09 (CH) 165.94 (C) 166.35 (C) **GC-MS** (EI) 230 ([M]⁺, 21%) 202 (10%) 171 (10%) 163 (100%) 135 (25%) 103 (24%) 76 (26%) 50 (14%).

(4-nitrophenyl)(1H-pyrazol-1-yl)methanone, 6g (0.934 g, 86%) was prepared according to the general



procedure from 4-nitrobenzaldehyde, **4g** (0.756 g, 0.005 mol). The desired acyl pyrazole, **6g**, was isolated as a powdery off-white solid. ¹H NMR (CDCl₃, 300 MHz) δ ppm 6.59 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.82 (d, *J*=0.66 Hz, 1 H) 8.25 - 8.38 (m, 4 H) 8.47 (d, *J*=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.65

(CH) 123.38 (CH) 130.66 (CH) 132.80 (CH) 137.34 (C) 145.57 (CH) 150.37 (C) 164.91 (C) **GC-MS** (EI) 217 ($[M]^+$, 29%) 201 (18%) 189 (25%) 165 (25%) 150 (100%) 120 (19%) 104 (84%) 92 (50%) 76 (82%) 64 (15%) 50 (45%) **HRMS** (DART) calcd for C₁₀H₈N₃O₃ [M+H]⁺: 218.0566, obs. 218.0568.

(2-nitrophenyl)(1*H*-pyrazol-1-yl)methanone,⁶ 6h (1.03 g, 95%) was prepared according to the general



procedure from 2-nitrobenzaldehyde, **4h** (0.756 g, 0.005 mol) *with the following modification:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction. The desired acyl pyrazole, **6h**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.52 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.63 (d, *J*=0.88 Hz, 1 H) 7.68 (dd, *J*=7.48, 1.32 Hz, 1 H) 7.72 (td, *J*=7.70, 1.32

Hz, 1 H) 7.81 (td, *J*=7.50, 1.10 Hz, 1 H) 8.24 (dd, *J*=8.14, 0.88 Hz, 1 H) 8.44 (d, *J*=2.86 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.73 (CH) 124.36 (CH) 129.19 (CH) 129.81 (CH) 130.17 (C) 131.75 (CH) 134.29 (CH) 145.47 (CH, C) 165.47 (C) GC-MS (EI) 217 ([M]⁺, 0.1%) 171 (100%) 150 (74%) 104 (13%) 78 (11%) 76 (45%) 51 (43%).

(2,5-dimethoxyphenyl)(1H-pyrazol-1-yl)methanone, 6i (1.02 g, 87%) was prepared according to the



general procedure from 2,5-dimethoxybenzaldehyde, **4i** (0.831 g, 0.005 mol). The desired acyl pyrazole, **6i**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.75 (s, 3 H) 3.79 (s, 3 H) 6.48 (dd, *J*=2.86, 1.32 Hz, 1 H) 6.92 - 7.09 (m, 3 H) 7.73 (d, *J*=0.66 Hz, 1 H) 8.32 (dd, *J*=2.86, 0.44 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 55.96 (CH₃) 56.66 (CH₃) 109.80 (CH) 113.29 (CH) 114.88

(CH) 118.34 (CH) 132.52 (CH) 129.56 (CH) 144.75 (C) 151.67 (C) 153.28 (C) 166.36 (C) **GC-MS** (EI) 232 ($[M]^+$, 45%) 201 (100%) 165 (100%) 150 (18%) 122 (25%) 107 (40%) 92 (13%) 79 (26%) 77 (21%) 63 (9%) 53 (9%) **HRMS** (DART) calcd for C₁₂H₁₃N₂O₃ [M+H]: 233.0926, obs. 233.0939.

(2-bromo-4-fluorophenyl)(1H-pyrazol-1-yl)methanone,⁶ 6j (1.27 g, 95%) was prepared according to the



general procedure from 2-bromo-4-fluorobenzaldehyde, **4j** (1.02 g, 0.005 mol).The desired acyl pyrazole, **6j**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 100 MHz) δ ppm 6.55 (dd, *J*=2.92, 1.41 Hz, 1 H) 7.16 (td, *J*=8.30, 2.40 Hz, 1 H) 7.42 (dd, *J*=8.10, 2.45 Hz, 1 H) 7.52 (dd, *J*=8.57, 5.75 Hz, 1 H) 7.76 (d, *J*=0.75 Hz, 1 H) 8.39 (dd, *J*=2.83, 0.57 Hz, 1 H)¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.84 (CH)

114.80 (d, $J_{C-C-F}=22.01$ Hz, CH) 121.01 (d, $J_{C-C-F}=24.94$ Hz, CH) 121.75 (d, $J_{C-C-C-F}=9.90$ Hz, C) 129.65 (CH) 131.75 (d, $J_{C-C-C-F}=9.17$ Hz, CH) 131.64 (d, $J_{C-C-C-F}=3.85$ Hz, C) 145.54 (CH) 163.69 (d, $J_{C-F}=256.03$ Hz, CF) 165.77 (C) ¹⁹F NMR (CDCl₃, 377 MHz) -109.65 – -109.56 (m, 1 F) GC-MS (EI) 270 ([M]⁺, ⁸¹Br, 0.1%) 268 ([M]⁺, ⁷⁹Br, 0.1%) 203 (⁸¹Br, 40%) 201 (⁷⁹Br, 42%) 189 (100%) 175 (⁸¹Br, 20%) 173 ([⁷⁹Br, 21%) 94 (41%) 74 (8%) 50 (6%)

(3-bromophenyl)(1*H*-pyrazol-1-yl)methanone,⁶ 6k (0.786 g, 63%) was prepared according to the general procedure from 3-bromobenzaldehyde, 4k (0.925 g, 0.005 mol). The desired acyl pyrazole, 6k, was isolated



as a viscous, clear, colorless oil. ¹H NMR (CDCl₃, 300 MHz) δ ppm 6.54 (dd, *J*=2.83, 1.51 Hz, 1 H) 7.38 (t, *J*=8.01 Hz, 1 H) 7.73 (dq, *J*=7.91, 0.90 Hz, 1 H) 7.81 (d, *J*=0.70 Hz, 1 H) 8.08 (dt, *J*=7.82, 1.18 Hz, 1 H) 8.29 (t, *J*=1.79 Hz, 1 H) 8.43 (d, *J*=2.83 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 109.90 (CH) 122.18 (C) 129.69 (CH) 130.25

(CH) 130.51 (CH) 133.40 (C) 134.47 (CH) 135.95 (CH) 144.90 (CH) 164.87 (C) **GC-MS** (EI) 252 ($[M]^+$, ⁸¹Br, 32%) 250 ($[M]^+$, ⁷⁹Br, 33%) 225 (23%, ⁸¹Br) 223(23%, ⁷⁹Br) 185(99%, ⁸¹Br) 183 (100%, ⁷⁹Br) 157(70%, ⁸¹Br) 155(71%, ⁷⁹Br) 76 (58%) 50 (37%).

(5-bromothiophen-2-yl)(1H-pyrazol-1-yl)methanone,⁶ 6l (1.24 g, 96%) was prepared according to the



general procedure from 5-bromothiophene-2-carbaldehyde, **4l** (0.955 g, 0.005 mol) *with the following modification:* Further purification was accomplished by washing the crude solid with hexanes. The desired acyl pyrazole, **6l**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.52 (dd, *J*=2.75, 1.43 Hz, 1 H) 7.17 (d, *J*=4.18 Hz, 1 H) 7.80 (s, 1 H) 8.13 (d, *J*=4.18 Hz, 1 H) 8.40 (d, *J*=2.64 Hz, 1 H) ¹³C

NMR (CDCl₃, 100 MHz) δ ppm 110.25 (CH) 127.38 (C) 129.74 (CH) 130.44 (CH) 132.89 (C) 138.74 (CH) 144.22 (CH) 157.79 (C) **GC-MS** (EI) 258 ([M]⁺, ⁸¹Br, 38%) 256 ([M]⁺, ⁷⁹Br, 37%) 230 (⁸¹Br, 41%) 228 (⁷⁹Br, 41%) 191 (⁸¹Br, 100%) 189 (⁷⁹Br, 99%) 163 (⁸¹Br, 12%) 161 (⁷⁹Br, 12%) 119 (⁸¹Br, 12%) 117 (⁷⁹Br, 12%) 82 (43%) 38 (12%).

(2-chloroquinolin-3-yl)(1H-pyrazol-1-yl)methanone, 4m (1.07 g, 83%) was prepared according to the



general procedure from 2-chloroquinoline-3-carbaldehyde, **4m** (0.958 g, 0.005 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used 2) EtOAc was used in place of Et₂O in the workup. The desired acyl pyrazole, **6m**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.61 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.66 (ddd, *J*=8.50, 7.00, 1.30 Hz, 1 H) 7.78 (d, *J*=0.88 Hz, 1 H)

7.86 (ddd, J=8.47, 7.04, 1.43 Hz, 1 H) 7.91 (d, J=8.36 Hz, 1 H) 8.11 (d, J=8.58 Hz, 1 H) 8.41 (s, 1 H) 8.48 (d, J=2.86 Hz, 1 H) ¹³**C** NMR (CDCl₃, 100 MHz) δ ppm 111.06 (CH) 125.80 (C) 127.51 (C) 128.18 (CH) 128.53 (CH) 128.93 (CH) 129.54 (CH) 132.51 (CH) 139.65 (CH) 145.64 (CH) 146.57 (C) 148.35 (C) 164.57 (C) **GC-MS** (EI) 257 ([M]⁺, 0.1%) 222 (100%) 190 (36%) 162 (40%) 127 (20%) 101 (33%) 75 (22%) 51 (11%) 40 (18%) **HRMS** (DART) calcd for C₁₃H₉ClN₃O [M+H]⁺: 258.0434, obs. 258.0438.

naphthalen-1-yl(1*H***-pyrazol-1-yl)methanone, ⁷ 6n** (0.892 g, 80%) was prepared according to the general procedure from 1-naphthaldehyde, **4n** (0.781 g, 0.005 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used 2) Further purification was accomplished by washing the crude solid with hexanes. The desired acyl pyrazole, **6n**, was isolated as a powdery pale yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.58 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.52 - 7.63 (m, 3 H) 7.78 (d, *J*=0.88 Hz, 1 H) 7.84 (dd, *J*=7.15, 1.21 Hz, 1 H) 7.91 - 7.97 (m, 1 H) 7.98 - 8.05 (m, 1 H) 8.08 (d, *J*=8.36 Hz, 1 H) 8.50 (dd, *J*=2.86, 0.44 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 110.21 (CH) 124.50 (CH) 125.23 (CH) 126.79 (CH)

⁷ Liu, Z.; Zhang, J.; Chen, S.; Shi, E.; Xu, Y.; Wan, X. Angew. Chem., Int. Ed. **2012**, *51*, 3231.

127.80 (CH) 128.83 (CH) 129.13 (CH) 130.02 (C) 130.34 (CH) 131.12 (C) 132.44 (CH) 133.75 (C) 145.10 (CH) 167.62 (C) **GC-MS** (EI) 222 ([M]⁺, 27%) 194 (11%) 155 (82%) 127 (100%) 77 (12%) 51 (5%).

(2-chloropyridin-3-yl)(1*H*-pyrazol-1-yl)methanone,⁶ 60 (0.798 g, 77%) was prepared according to the



general procedure from 2-chloronicotinaldehyde, **40** (0.707 g, 0.005 mol) *with the following modification:* EtOAc was used in place of Et₂O in the workup. The desired acyl pyrazole, **60**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.57 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.38 (dd, *J*=7.70, 4.84 Hz, 1 H) 7.75 (d, *J*=0.66 Hz, 1 H) 7.87 (dd, *J*=7.59, 1.87 Hz, 1 H) 8.40 (d, *J*=2.86 Hz, 1 H) 8.55 (dd, *J*=4.84, 1.76 Hz,

1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 111.13 (CH) 122.00 (CH) 129.46 (CH) 130.07 (C) 138.73 (CH) 145.74 (CH) 148.60 (C) 151.59 (CH) 164.45 (C) GC-MS (EI) 172 ([M-Cl]⁺, 100%) 142 (16%) 140 (49%) 114 (14%) 112 (44%) 76 (28%) 50 (13%) HRMS (DART) calcd for C₉H₆ClN₃O [M+H]: 208.0278, found: 208.0302.

cyclohexyl(1*H*-**pyrazol-1-yl)methanone**,⁶ **6p** (0.698 g, 78%) was prepared according to the general procedure from cyclohexanecarbaldehyde, **4p** (0.561 g, 0.005 mol). The desired acyl pyrazole, **6p**, was isolated as a clear, pale brown oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.28 (tt, *J*=12.32, 3.30 Hz, 1 H) 1.41 (qt, *J*=12.64, 3.16 Hz, 2 H) 1.55 (qd, *J*=12.10, 3.08 Hz, 2 H) 1.68 - 1.77 (m, 1 H) 1.82 (dt, *J*=13.04, 3.27 Hz, 2 H) 1.93 - 2.02 (m, 2 H) 3.62 (tt, *J*=11.58, 3.49 Hz, 1 H) 6.41 (dd, *J*=2.75, 1.43 Hz, 1 H) 7.69 (s, 1 H) 8.22 (d, *J*=2.86 Hz, 1 H) ¹³C NMR

 $(CDCl_3, 100 \text{ MHz}) \delta \text{ ppm } 25.30 (CH_2) 25.66 (CH_2) 28.96 (CH_2) 41.40 (CH) 109.21 (CH) 128.22 (CH) 143.58 (CH) 174.88 (C)$ **GC-MS**(EI) 178 ([M]⁺, 3%) 110 (10%) 83 (37%) 69 (100%) 55 (34%) 41 (23%) 39 (16%)**HRMS**(DART) calcd for C₁₀H1₄N₂O [M+H]: 179.1184, found: 179.1202.

3-phenyl-1-(1*H***-pyrazol-1-yl)propan-1-one,⁸ 6q** (0.744 g, 74%) was prepared according to the general procedure from 2-methyl-2-phenylpropanal, **4q** (0.670 g, 0.005 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used: 2) 3 Å

following modifications: 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction; 3) Further purification was accomplished by SiO₂ plug, eluting with 95:5 Hex/EtOAc. The desired acyl pyrazole,

6q, was isolated as a clear, pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.13 (t, *J*=7.70 Hz, 2 H) 3.49 (t, *J*=7.90 Hz, 2 H) 6.44 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.18 - 7.24 (m, 1 H) 7.25 - 7.35 (m, 4 H) 7.70 (d, *J*=0.66 Hz, 1 H) 8.26 (d, *J*=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 30.11 (CH₂) 35.54 (CH₂) 109.48 (CH) 126.25 (CH) 128.15 (CH) 128.36 (CH) 128.45 (CH) 140.23 (C) 143.86 (CH) 171.25 (C) **GC-MS** (EI) 200 ([M]⁺, 4%) 131 (6%) 104 (100%) 91 (34%) 77 (17%) 69 (42%) 51 (8%).

1-(1H-pyrazol-1-yl)dodecan-1-one,⁶ 6r (0.987 g, 79%) was prepared according to the general procedure



6q

from dodecanal, **4r** (0.921 g, 0.005 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction; 3) Further purification was accomplished by SiO₂ plug, eluting with 95:5 Hex/EtOAc. The desired

acyl pyrazole, **6r**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 0.88 (t, *J*=7.00 Hz, 3 H) 1.17 - 1.46 (m, 16 H) 1.78 (quin, *J*=7.48 Hz, 2 H) 3.12 (t, *J*=7.48 Hz, 2 H) 6.43 (dd, *J*=2.86, 1.54

⁸ Holzer, W.; Pöecher, I. J. Heterocyclic Chem. 1995, 32, 189.

Hz, 1 H) 7.70 (d, J=0.88 Hz, 1 H) 8.26 (d, J=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 14.34 (CH₃) 22.92 (CH₂) 24.63 (CH₂) 29.37 (CH₂) 29.55 (2 × CH₂) 29.69 (CH₂) 29.84 (2 × CH₂) 32.14 (CH₂) 34.19 (CH₂) 109.61 (CH) 128.42 (CH) 144.01 (CH) 172.59 (C) **GC-MS** (EI) 250 ([M]⁺, 1%) 249 (4%) 182 (5%) 110 (34%) 98 (22%) 84 (21%) 82 (17%) 69 (100%) 57 (15%) 55 (32%) 43 (17%) 41 (29%) **HRMS** (DART) calcd for C₁₅H₂₆N₂O [M+H]: 251.2123, found: 251.2127.

p-toluoyl-1*H*-1,2,3-benzotriazole,⁹ 6s (0.792 g, 67%) was prepared according to the general procedure from *p*-tolualdehyde 4a (0.601 g, 0.005 mol) and 1*H*-benzotriazole, 5b (0.893 g, 0.0075 mol) with the following modifications: 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 2 M HCl was used in place of 0.5 M HCl in the work-up. The desired acyl azole, 6s, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.49 (s, 3 H) 7.39 (d, *J*=8.14 Hz, 2 H) 7.55 (td, *J*=7.70, 0.88 Hz, 1 H)

7.71 (td, *J*=7.70, 0.88 Hz, 1 H) 8.11 - 8.20 (m, 3 H) 8.39 (d, *J*=8.36 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 22.08 (CH₃) 115.10 (CH) 120.42 (CH) 126.51 (CH) 128.91 (C) 129.49 (CH) 130.56 (CH) 132.22 (CH) 132.74 (C) 145.14 (C) 146.03 (C) 166.86 (C) **GC-MS** (EI) 237 ([M]⁺, 7%) 209 (72%) 180 (14%) 119 (100%) 91 (65%) 65 (30%) 39 (9%).

(3-phenyl-1*H*-pyrazol-1-yl)(*p*-tolyl)methanone,⁶ 6t (1.03 g, 79%) was prepared according to the general



procedure from *p*-tolualdehyde **4a** (0.601 g, 0.005 mol) and 3-phenyl-1*H*-pyrazole, **5c** (1.44 g, 0.010 mol, 2 equiv). The desired acyl azole, **6t**, was isolated as a powdery pale yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.47 (s, 3 H) 6.85 (d, *J*=2.86 Hz, 1 H) 7.33 (d, *J*=7.92 Hz, 2 H) 7.36 - 7.47 (m, 3 H) 7.85 - 7.92 (m,

2 H) 8.20 (d, *J*=8.36 Hz, 2 H) 8.46 (d, *J*=3.08 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 22.02 (CH₃) 107.24 (CH) 126.67 (CH) 128.93 (C) 129.02 (CH) 129.09 (CH) 129.40 (CH) 132.05 (CH) 132.23 (C) 132.39 (CH) 144.23 (C) 156.00 (C) 166.26 (C) GC-MS (EI) 262 ([M]⁺, 27%) 234 (3%) 119 (100%) 91 (35%) 65 (13%) 51 (2%).

ethyl 1-(4-methylbenzoyl)-1H-pyrazole-4-carboxylate,⁶ 6u (0.845 g, 65%) was prepared according to the



general procedure from *p*-tolualdehyde **4a** (0.601 g, 0.005 mol) and ethyl 1*H*pyrazole-4-carboxylate, **5d** (1.05 g, 0.0075 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 2 M HCl was used in place of 0.5 M HCl in the work-up. The desired acyl azole, **6u**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.38 (t, *J*=7.30 Hz, 3 H) 2.45 (s,

3 H) 4.35 (q, *J*=7.04 Hz, 2 H) 7.32 (d, *J*=7.92 Hz, 2 H) 8.06 (d, *J*=8.36 Hz, 2 H) 8.12 (s, 1 H) 8.86 (s, 1 H) ¹³C NMR (CDCl₃, 400 MHz) δ ppm 14.55 (CH₃) 22.01 (CH₃) 61.14 (CH₂) 118.30 (CH) 127.83 (C) 129.27 (CH) 132.18 (CH) 133.99 (CH) 144.27 (CH) 145.06 (C) 162.40 (C) 166.03 (C) GC-MS (EI) 258 ([M]⁺, 11%) 230 (6%) 119 (100%) 91 (29%) 65 (9%).

⁹ Katritzky, A. R.; Huang, T.-B.; Voronkov, M. V. J. Org. Chem., 2001, 66, 1043.

(4-chloro-1*H*-pyrazol-1-yl)(p-tolyl)methanone,⁶ 6v (0.566 g, 51%) was prepared according to the general



procedure from *p*-tolualdehyde **4a** (0.601 g, 0.005 mol) and 4-chloro-1*H*-pyrazole, **5e** (0.769 g, 0.0075 mol) *with the following modifications:* 1) 5 equiv of pyridine (1.98 g, 0.025 mol) was used; 2) 3 Å molecular sieves (0.190 g) were used in the reaction. The desired acyl azole, **6v**, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.44 (s, 3 H) 7.31 (d, *J*=7.92 Hz, 2 H) 7.70 (s, 1

H) 8.01 (d, *J*=8.36 Hz, 2 H) 8.38 (d, *J*=0.66 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 21.99 (CH₃) 115.51 (C) 127.89 (C) 128.11 (CH) 129.20 (CH) 131.99 (CH) 143.09 (CH) 144.66 (C) 165.58 (C) GC-MS (EI) 220 ([M]⁺, 17%) 119 (100%) 91 (36%) 65 (13%) 51 (2%) 39 (3%).

(4-bromo-1*H*-pyrazol-1-yl)(*p*-tolyl)methanone,⁶ 6w (1.18 g, 89%) was prepared according to the general



procedure from *p*-tolualdehyde, **2a** (0.601 g, 5 mmol) and 4-bromo-1*H*-pyrazole, **5f** (1.10 g, 0.0075 mol) 2) 2 M HCl was used in place of 0.5 M HCl in the work-up. The desired acyl azole, **6w**, was isolated as a powdery off-white solid. ¹**H NMR** (CDCl₃, 300 MHz) δ ppm 2.45 (s, 3 H) 7.31 (d, *J*=7.91 Hz, 2 H) 7.73 (s, 1 H) 8.01 (d, *J*=8.10

Hz, 2 H) 8.44 (s, 1 H) 13 C NMR (CDCl₃, 100 MHz) δ ppm 22.03 (CH₃) 99.35 (C) 127.91 (C) 129.25 (CH) 130.59 (CH) 132.01 (CH) 144.73 (C) 144.97 (CH) 165.48 (C) GC-MS (EI) 266 ([M]⁺, 81 Br, 12%) 264 ([M]⁺, 79 Br, 12%) 119 (100%) 91 (46%) 65 (20%) 38 (6%).



(1*H*-pyrazol-1-yl)(*p*-tolyl)methanone⁶ (6a)

To a 20-mL vial equipped with a stir bar was added *p*-tolylcarbinol **7a** (0.610 g, 0.005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole (0.511 g, 0.0075 mol, 1.5 equiv), 3Å molecular sieves (0.190 g), pyridine (1.98 g, 0.025 mol), and MeCN (10 mL, 0.5 M). The reaction mixture was was stirred for about two minutes at room temperature. After this time, sodium persulfate (5.95 g, 0.025 mol, 5 equiv) and the photocatalyst Ru(bpy)₃(PF₆)₂ (0.086 g, 0.0001 mol, 0.02 equiv) were added. The vial was sealed with a cap and the vial was irradiated in the aforementioned LED reactor for 24 h. After this time, Et₂O (10 mL) was added and the resulting mixture was filtered through a coarse porosity fritted glass funnel. The solution was then transferred to a separatory funnel, diluted with Et₂O (50 mL) and 0.5 M aqueous HCl (75 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3 × 75 mL). The organic layers were then combined and washed with 0.5 M aqueous HCl (3 × 50 mL), saturated aqueous sodium bicarbonate (50 mL), deionized water (50 mL), and finally brine (100 mL). The organics were then dried over sodium sulfate and the solvent removed *in vacuo* to afford the crude *N*-acyl pyrazole which was further purified by recrystallization to give the pure *N*-acyl pyrazole (0.468 g, 50%) as powdery pale yellow solid.

¹H NMR (CDCl₃, 400 MHz) δ ppm 2.44 (s, 3 H) 6.51 (dd, *J*=2.75, 1.43 Hz, 1 H) 7.31 (d, *J*=8.14 Hz, 2 H) 7.79 (d, *J*=0.66 Hz, 1 H) 8.05 (d, *J*=8.14 Hz, 2 H) 8.43 (dd, *J*=2.86, 0.44 Hz, 1 H)
¹³C NMR (CDCl₃, 100 MHz) δ ppm 21.98 (CH₃) 109.50 (CH) 128.91 (C) 129.12 (CH 130.69 (CH) 131.95 (CH) 144.23 (C) 144.56 (CH) 166.57 (C)
GC-MS (EI) 186 ([M]⁺, 23%) 158 (13%) 119 (100%) 91 (50%) 65 (19%) 63 (6%)

(4-fluorophenyl)(1H-pyrazol-1-yl)methanone, 6c (0.744 g, 78%) was prepared according to the general procedure from 4-fluorobenzyl alcohol, 7c (0.630 g, 0.005 mol). The desired acyl pyrazole, 6c, was isolated as a powdery white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.55 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.20 (tt, *J*=8.60, 2.90 Hz, 2 H) 7.82 (d, *J*=0.66 Hz, 1 H) 8.15 - 8.32 (m, 2 H) 8.46 (d, *J*=2.42 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz)

δ ppm 109.79 (CH) 115.67 (d, J_{C-C-F} =22.01 Hz, CH) 127.85 (d, $J_{C-C-C-F}$ =3.12 Hz, C) 130.82 (CH) 134.77 (d, $J_{C-C-C-F}$ =9.17 Hz, CH) 144.85 (CH) 165.99 (d, J_{C-F} =255.29 Hz, CF) 165.34 (s, C). ¹⁹F NMR (CDCl₃, 377 MHz) δ ppm -107.95 – -107.82 (m, 1 F) GC-MS (EI) 190 ([M]⁺, 14%) 162 (12%) 123 (100%) 95 (70%) 75 (29%) 50 (7%) HRMS (DART) calcd for C₁₀H₈FN₂O [M+H]⁺: 191.0621, obs. 191.0609.

(1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone,⁶ 6d (0.793 g, 66%) was prepared according to



the general procedure from was prepared according to the general procedure from 4-(trifluoromethyl)benzyl alcohol, **7d** (0.881 g, 0.005 mol). The desired acyl pyrazole, **6d**, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.59 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.80 (d, *J*=8.14 Hz, 2 H) 7.84 (d, *J*=0.66 Hz, 1 H) 8.26 (d, *J*=8.14 Hz, 2 H) 8.49 (d, *J*=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz)

δ ppm 110.25 (CH) 123.80 (q, J_{C-F} =272.30 Hz, CF₃) 125.28 (q, J_{C-C-F} =3.60 Hz, CH) 130.59 (CH) 132.02 (CH) 134.48 (q, J_{C-C-F} =32.10 Hz, C) 135.08 (C) 145.22 (CH) 165.52 (C) ¹⁹F NMR (CDC13, 377 MHz) - 114.53 (s, 3 F) GC-MS (EI) 240 ([M]⁺, 25%) 212 (13%) 173 (100%) 145 (89%) 125 (12%) 95 (14%) 75 (13%) 69 (5%) 50 (6%)

4-(1H-pyrazole-1-carbonyl)benzonitrile,⁶ 6e (0.769 g, 78%) was prepared according to the general



procedure from was prepared according to the general procedure from 4-cyanobenzyl alcohol, **7e** (0.665 g, 0.005 mol) *with the following modification:* No molecular sieves were used. The desired acyl pyrazole, **6e**, was isolated as a powdery off-white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.57 (dd, *J*=2.86, 1.54 Hz, 1 H) 7.77 - 7.83 (m, 3 H) 8.23 (d, *J*=8.58 Hz, 2 H) 8.45 (d, *J*=2.86 Hz, 1 H) ¹³C NMR (CDCl₃,

100 MHz) δ ppm 110.48 (CH) 116.47 (C) 118.08 (C) 130.61 (CH) 131.99 (CH) 132.16 (CH) 135.65 (C) 145.40 (CH) 165.03 (C) **GC-MS** (EI) 197 ([M]⁺, 21%) 169 (17%) 130 (100%) 102 (71%) 76 (13%) 75 (20%) 51 (11%).

(2-chloropyridin-3-yl)(1H-pyrazol-1-yl)methanone,6 60 (0.892 g, 86%) was prepared according to the



general procedure from (2-chloropyrid-3-yl)methanol, **70** (0.717 g, 0.005 mol). The desired acyl pyrazole, **60**, was isolated as a powdery yellow solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 6.57 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.38 (dd, *J*=7.70, 4.84 Hz, 1 H) 7.75 (d, *J*=0.66 Hz, 1 H) 7.87 (dd, *J*=7.59, 1.87 Hz, 1 H) 8.40 (d, *J*=2.86 Hz, 1 H) 8.55 (dd, *J*=4.84, 1.76 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 111.13 (CH) 122.00 (CH) 129.46

(CH) 130.07 (C) 138.73 (CH) 145.74 (CH) 148.60 (C) 151.59 (CH) 164.45 (C) **GC-MS** (EI) 172 ([M-Cl]⁺, 100%) 142 (16%) 140 (49%) 114 (14%) 112 (44%) 76 (28%) 50 (13%)

(3-methyloxetan-3-yl)(1*H*-pyrazol-1-yl)methanone, 6x (0.436 g, 52%)¹⁰ was prepared according to the general procedure from (3-methyloxetan-3-yl)methanol, 7x (0.510 g, 0.005 mol). The desired acyl pyrazole, 6x, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.88 (s, 3 H) 4.53 (d, *J*=6.82 Hz, 2 H) 5.10 (d, *J*=6.60 Hz, 2 H) 6.43 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.67 (d, *J*=0.66 Hz, 1 H) 8.16 - 8.23 (m, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 24.26 (CH₃) 46.86 (C) 79.76 (CH₂) 109.79 (CH) 128.83 (CH) 144.68 (CH) 173.53

(C) **GC-MS** (EI) 166 ($[M]^+$, 0.1%) 136 (10%) 108 (13%) 81 (11%) 69 (100%), 41 (74%) **HRMS** (DART) calcd for C₈H₁₁N₂O₂ [M+H]⁺: 167.0821, found: 167.0807.

¹⁰ This compound is quite volatile and thus care must be taken during rotary evaporation. We found a room temperature water bath (24 °C) at 450 mmHg was ideal for solvent removal.

$(1H\-pyrazol-1\-yl)((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7,7\-tetramethyltetrahydro\-3aH\-bis([1,3]dioxolo)[4,5-1]))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,5aR,8aS,8bR)\-2,2,7))((3aR,5S,$



b:4',5'-*d*]pyran-5-yl)methanone,⁶ 6y (1.18 g, 73%) was prepared according to the general procedure from 1,2:3,4-di-*O*-isopropylidene-α-D-galactopyranose, 7y (1.30 g, 0.005 mol). The desired acyl pyrazole, 6y, was isolated as a powdery off-white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.28 (s, 3 H) 1.37 (s, 3 H) 1.49 (s, 3 H) 1.59 (s, 3 H) 4.47 (dd, *J*=5.17, 2.75 Hz, 1 H) 4.71 (dd, *J*=7.48, 2.86 Hz, 1 H) 4.96 (dd, *J*=7.48, 2.42 Hz, 1 H) 5.59 (d, *J*=2.42 Hz, 1 H) 5.76 (d, *J*=5.06 Hz, 1 H) 6.45 (dd, *J*=2.86, 1.32 Hz, 1 H) 7.71 (s, 1 H) 8.31 (d, *J*=2.86 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 25.14

 $\begin{array}{l} ({\rm CH}_3)\ 25.20\ ({\rm CH}_3)\ 26.17\ ({\rm CH}_3)\ 26.29\ ({\rm CH}_3)\ 69.42\ ({\rm CH})\ 70.62\ ({\rm CH})\ 71.49\ ({\rm CH})\ 72.82\ ({\rm CH})\ 96.92\ ({\rm CH})\ 109.58\ ({\rm C})\ 109.82\ ({\rm CH})\ 110.80\ ({\rm C})\ 129.13\ ({\rm CH})\ 144.60\ ({\rm CH})\ 165.98\ ({\rm C})\ {\rm GC-MS}\ ({\rm EI})\ 309\ ([{\rm M-CH}_3]^+,\ 35\%)\ 239\ (6\%)\ 199\ (6\%)\ 163\ (5\%)\ 141\ (47\%)\ 113\ (29\%)\ 100\ (16\%)\ 95\ (26\%)\ 85\ (28\%)\ 83\ (17\%)\ 71\ (23\%)\ 69\ (43\%)\ 59\ (34\%)\ 43\ (100\%)\ 41\ (16\%). \end{array}$

1-(1H-pyrazol-1-yl)-3-(trimethylsilyl)propan-1-one, 6z (0.411 g, 42%) was prepared according to the



general procedure from 3-(trimethylsilyl)-1-propanol, **7z** (0.661 g, 0.005 mol) *with the following modification:* Further purification was accomplished by SiO₂ plug, eluting with 95:5 to 9:1 Hex/EtOAc. The desired acyl pyrazole, **6z**, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 0.07 (s, 9 H) 0.84 - 1.06 (m, 2 H) 2.98

- 3.28 (m, 2 H) 6.44 (dd, J=2.75, 1.43 Hz, 1 H) 7.71 (d, J=0.66 Hz, 1 H) 8.26 (d, J=2.64 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm -1.60 (CH₃) 11.26 (CH₂) 29.02 (CH₂) 109.62 (CH) 128.61 (CH) 144.04 (CH) 173.89 (C) GC-MS (EI) 196 ([M]⁺, 2%) 195 ([M-H]⁺, 12%) 181 (59%) 169 (14%) 167 (12%) 153 (33%) 141 (29%) 125 (100%) 113 (13%) 98 (10%) 85 (9%) 73 (76%) 69 (19%) 43 (16%) 41 (14%) HRMS (DART) calcd for C₉H₁₇N₂OSi [M+H]⁺: 197.1110, obs. 197.1118.

cyclobutyl(1H-pyrazol-1-yl)methanone,¹⁰ 6aa (0.246 g, 33%) was prepared according to the general



procedure from cyclobutylmethanol, **7aa** (0.240 g, 0.500) was prepared according to the general procedure from cyclobutylmethanol, **7aa** (0.420 g, 0.005 mol) with the following modification: Further purification was accomplished by SiO₂ plug, eluting with 95:5 Hex/EtOAc. The desired acyl pyrazole, **6aa**, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.87 - 2.18 (m, 2 H) 2.23 - 2.53 (m, 4 H) 4.27 (quind, *J*=8.57,

0.94 Hz, 1 H) 6.41 (dd, *J*=2.73, 1.41 Hz, 1 H) 7.67 (d, *J*=0.56 Hz, 1 H) 8.23 (dd, *J*=2.83, 0.38 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 18.43 (CH₂) 25.24 (CH₂) 37.68 (CH) 109.29 (CH) 128.30 (CH) 143.83 (CH) 173.56 (C) GC-MS (EI) 150 ([M]⁺, 2%) 122 (21%) 94 (23%) 82 (13%) 69 (71%), 55 (100%) HRMS (DART) calcd for C₈H₁₁N₂O [M+H]⁺: 151.0871, found: 151.0865.

tert-butyl 4-(1*H*-pyrazole-1-carbonyl)piperidine-1-carboxylate, 6ab (0.876 g, 63%) was prepared according to the general procedure from *tert*-butyl 4-(hydroxymethyl)piperidine-1carboxylate, 7ab (1.08 g, 0.005 mol) with the following modification: Further purification was accomplished by SiO₂ plug, eluting with 8:2 Hex/EtOAc.The desired acyl pyrazole, 6ab, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.50 (s, 9 H), 1.79 (qd, J=11.9, 4.4 Hz, 2 H), 1.93 - 2.06 (m, 2 H), 2.93 (t, J=12.8)

Hz, 2 H), 3.82 (tt, *J*=11.7, 3.7 Hz, 1 H), 4.08 - 4.32 (m, 2 H), 6.48 (dd, *J*=2.8, 1.4 Hz, 1 H), 7.75 (d, *J*=0.9 Hz, 1 H), 8.27 (d, *J*=2.9 Hz, 1 H) ¹³**C** NMR (CDCl₃, 100 MHz) δ ppm 28.30 (CH₂), 28.62 (CH₃), 40.02 (CH), 43.09 (CH₂), 79.79 (C), 109.89 (CH), 128.65 (CH), 144.23 (CH), 154.81 (C), 173.73 (C) **GC-MS** (EI) 279 ([M]⁺, 0.1%) 222 (33%) 206 (12%) 178 (7%) 138 (14%) 127 (35%) 110 (5%) 95 (7%) 83 (74%)

69 (39%) 57 (100%) 41 (28%) **HRMS** (DART) calcd for $C_{10}H_{12}N_3O_3$ [M - ^{*t*}Bu]⁺: 222.0879, found: 222.0889.

(S)-tert-butyl 2-(1H-pyrazole-1-carbonyl)pyrrolidine-1-carboxylate,¹¹ 6ac (0.939 g, 71%) was prepared



according to the general procedure from (*S*)-*tert*-butyl 2-(hydroxymethyl)pyrrolidine-1carboxylate, **7ac** (1.06 g, 0.005 mol) *with the following modification:* Further purification was accomplished by SiO₂ column chromatography, eluting with 7:3 Hex/EtOAc. The desired acyl pyrazole, **6ac**, was isolated as a pale yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.28 & 1.49 (s, 9 H), 1.87 - 2.14 (m, 3 H), 2.34 - 2.53 (m, 1

H), 3.44 - 3.75 (m, 2 H), 5.52 - 5.63 (m, 1 H), 6.44 & 6.49 (dd, J=2.4, 1.3 Hz & dd, J=2.7, 1.4 Hz, 1 H), 7.72 & 7.75 (s, 1 H), 8.27 & 8.30 (d, J=2.8 Hz, & d, J=2.8 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 24.12 & 24.64 (CH₂), 28.34 & 28.74 (CH₃), 30.74 & 31.55 (CH₂), 46.94 & 47.26 (CH₂), 58.36 & 58.64 (CH), 80.21 & 80.24 (s, 1 C), 109.80 & 110.07 (CH), 128.82 & 129.18 (CH), 144.41 (CH), 153.87 & 154.67 (C), 171.30 & 171.99 (C) **GC-MS** (EI) 266 ([M]⁺, 0.1%) 209 (2%) 197 (8%) 192 (7%) 170 (12%) 164 (35%) 141 (47%) 114 (78%) 95 (5%) 70 (100%) 57 (86%) 41 (45%) HRMS (DART) calcd for C₁₃H₂₀N₃O₃ [M+H]⁺: 266.1505, found: 266.1479.

¹¹ NMR spectra of this compound indicates significant rotameric character; values for all rotameric carbons and protons signals are given. A Coalesce study is included in spectral data section of this Supporting Information.

From Aldehydes



4-cyano-*N*-cyclohexylbenzamide,¹² 8e

Stage One:

To a 20-mL vial equipped with a stir bar was added 4-formylbenzonitrile, **4e**, (0.656 g, 0.005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole (0.511 g, 0.0075 mol, 1.5 equiv), pyridine (0.978 g, 0.0125 mol, 2.5 equiv), and MeCN (10 mL, 0.5 M). The reaction mixture was stirred for two minutes and, after this time, sodium persulfate (2.62 g, 0.011 mol, 2.2 equiv) and Ru(bpy)₃(PF₆)₂ (0.086 g, 0.0001 mol, 0.02 equiv) were added. The vial was sealed with a cap and the vial was irradiated in the aforementioned LED reactor for 24 h. After this time, Et₂O (10 mL) was added and the resulting mixture was filtered through a coarse porosity fritted glass funnel. The solvent was then removed *in vacuo* to afford the crude *N*-acyl pyrazole which was used directly in the next step.

Stage Two:

To a 50 mL round bottom flask equipped with a stir bar was added the crude acyl pyrazole in MeCN (5 mL) and allowed to stir for 5 minutes. After this time, Et₃N (2.53 g, 3.48 mL, 0.025 mol, 5 equiv) was added all at once, followed by dropwise addition of freshly distilled cyclohexylamine (1.49 g, 1.72 mL, 0.015 mol, 3 equiv). The reaction was allowed to stir for 12 h at room temperature, and after this time, Et₂O (~ 20 mL) was added. The solution was then transferred to a separatory funnel and diluted with aqueous 0.5 M HCl (100 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3 × 50 mL). The combined organic layers were washed with 0.5 M HCl (3 × 50 mL), saturated aqueous NaHCO₃ (50 mL), deionized H₂O (50 mL), and brine (100 mL). The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo* to afford the pure amide **8e** (0.756 g, 66%) as a off-white powdery solid.

¹**H** NMR (CDCl₃, 400 MHz) δ ppm 1.20 - 1.33 (m, 3 H), 1.39 - 1.52 (m, 2 H), 1.70 (dt, *J*=13.0, 3.6 Hz, 1 H), 1.79 (dt, *J*=13.5, 3.7 Hz, 2 H), 2.01 - 2.12 (m, 2 H), 3.87 - 4.10 (m, 1 H), 5.98 (d, *J*=6.4 Hz, 1 H), 7.75 (d, *J*=8.4 Hz, 2 H), 7.87 (d, *J*=8.4 Hz, 2 H)

¹³C NMR (CDCl₃, 100 MHz) δ ppm 25.14 (CH₂), 25.77 (CH₂), 33.42 (CH₂), 49.42 (CH), 115.18 (C), 118.33 (C), 127.87 (CH), 132.69 (CH), 139.31 (C), 165.08 (C)

GC-MS (EI) 228 ([M]⁺, 11%) 185 (8%) 147 (77%) 130 (100%) 102 (61%) 82 (16%) 75 (11%) 67 (20%) 41 (13%)

From Alcohols

¹² Correa, A.; Martin, R. J. Am. Chem. Soc. 2014, 136, 7253.



2-bromo-N-cyclohexylbenzamide,13 8ad

Stage One:

To a 20-mL vial equipped with a stir bar was added 2-bromobenzyl alcohol, (0.935 g, 0.005 mol, 1 equiv), ACT (0.213 g, 0.001 mol, 0.2 equiv), pyrazole (0.511 g, 0.0075 mol, 1.5 equiv), pyridine (1.98 g, 0.025 mol, 5 equiv), and MeCN (10 mL, 0.5 M). The reaction mixture was stirred for two minutes and, after this time, sodium persulfate (5.95 g, 0.025 mol, 5 equiv) and Ru(bpy)₃(PF₆)₂ (0.086 g, 0.0001 mol, 0.02 equiv) were added. The vial was sealed with a cap and the vial was irradiated in the aforementioned LED reactor for 24 h. After this time, Et₂O (10 mL) was added and the resulting mixture was filtered through a coarse porosity fritted glass funnel. The solvent was then removed *in vacuo* to afford the crude *N*-acyl pyrazole which was used directly in the next step.

Stage Two:

To a 50 mL round bottom flask equipped with a stir bar was added the crude acyl pyrazole in MeCN (5 mL) and allowed to stir for 5 minutes. After this time, Et₃N (2.53 g, 3.48 mL, 0.025 mol, 5 equiv) was added all at once, followed by dropwise addition of freshly distilled cyclohexylamine (1.49 g, 1.72 mL, 0.015 mol, 3 equiv). The reaction was allowed to stir for 12 h at room temperature, and after this time, Et₂O (~ 20 mL) was added. The solution was then transferred to a separatory funnel and diluted with aqueous 0.5 M HCl (100 mL). The layers were separated and the aqueous layer was extracted with Et₂O (3 × 50 mL). The combined organic layers were washed with 0.5 M HCl (3 × 50 mL), saturated aqueous NaHCO₃ (50 mL), deionized H₂O (50 mL), and brine (100 mL). The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo* to afford the pure amide **8ad** (1.10 g, 78%) as a white powdery solid.

¹**H** NMR (CDCl₃, 400 MHz) δ ppm 1.17 - 1.37 (m, 3 H), 1.38 - 1.52 (m, 2 H), 1.66 (dt, J=12.9, 3.8 Hz, 1 H), 1.77 (dt, J=13.5, 3.9 Hz, 2 H), 2.02 - 2.13 (m, 2 H), 3.95 - 4.09 (m, 1 H), 5.86 (br. s., 1 H), 7.27 (td, J=7.5, 1.8 Hz, 1 H), 7.34 - 7.39 (m, 1 H), 7.53 (dd, J=7.6, 1.7 Hz, 1 H), 7.59 (dd, J=8.0, 1.0 Hz, 1 H) ¹³C NMR (CDCl₃, 100 MHz) δ ppm 25.03 (CH₂), 25.79 (CH₂), 33.18 (CH₂), 49.18 (CH), 119.48 (C), 127.79 (CH), 129.80 (CH), 131.28 (CH), 133.52 (CH), 138.53 (C), 166.92 (C) **GC-MS** (EI) 283 ([M]⁺, ⁸¹Br, 14%) 281 ([M]⁺, ⁷⁹Br, 15%) 202 (⁸¹Br, 74%) 200 (⁷⁹Br, 74%) 185 (⁸¹Br, 97%) 183 (⁷⁹Br, 100%) 157 (⁸¹Br, 37%) 155 (⁷⁹Br, 36%) 105 (17%) 82 (8%) 76 (38%) 67 (15%) 50 (18%) 41 (28%).

¹³ Wrobel, J.; Dietrich, A. *Heterocycles* **1994**, *38*, 1823.

¹H NMR Spectra of Synthesized Compounds

0







(4-methoxyphenyl)(1H-pyrazol-1-yl)methanone 400 MHz, CDCl3









(1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone 400 MHz, CDCl3













0

methyl 4–(1H–pyrazole–1–carbonyl)benzoate 400 MHz, CDCl3



















(2,5-dimethoxyphenyl)(1H-pyrazol-1-yl)methanone 400 MHz, CDCl3





















(2-chloroquinolin-3-yl)(1H-pyrazol-1-yl)methanone 400 MHz, CDCl3





naphthalen-1-yl(1H-pyrazol-1-yl)methanone 400 MHz, CDCl3

















3-phenyl-1-(1H-pyrazol-1-yl)propan-1-one 400 MHz, CDCl3



ö

1-(1H-pyrazol-1-yl)dodecan-1-one 400 MHz, CDCl3




p-toluoyl-1H-1,2,3-benzotriazole 400 MHz, CDCl3





(3-phenyl-1H-pyrazol-1-yl)(p-tolyl)methanone 400 MHz, CDCl3





ethyl 1–(4–methylbenzoyl)–1H–pyrazole–4–carboxylate 400 MHz, CDCl3



o

(4-chloro-1H-pyrazol-1-yl)(p-tolyl)methanone 400 MHz, CDCl3





(3-methyloxetan-3-yl)(1H-pyrazol-1-yl)methanone 400 MHz, CDCl3





 $(1H-pyrazol-1-yl)((3aR,5S,5aR,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl) methanone 400\ MHz, CDCl3$



1-(1H-pyrazol-1-yl)-3-(trimethylsilyl)propan-1-one 400 MHz, CDCl3













0

(S)-tert-butyl 2-(1H-pyrazole-1-carbonyl)pyrrolidine-1-carboxylate 400 MHz, CDCl3





0

4-cyano-N-cyclohexylbenzamide 400 MHz, CDCl3



¹³C NMR Spectra of Synthesized Compounds



21.94

200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm





0

(4-fluorophenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3



0

(1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone 100 MHz, CDCl3



4-(1H-pyrazole-1-carbonyl)benzonitrile 100 MHz, CDCl3





methyl 4–(1H–pyrazole–1–carbonyl)benzoate 100 MHz, CDCl3





(4-nitrophenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3







(2-nitrophenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3





(2,5-dimethoxyphenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3





(2-bromo-4-fluorophenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3







(3-bromophenyl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3



133.20 130.33 130.15 129.51 129.51

3)



 $(5-bromothiophen-2-yl)(1H-pyrazol-1-yl) methanone 100\ MHz,\ CDCl3$







naphthalen-1-yl(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3







(2-chloropyridin-3-yl)(1H-pyrazol-1-yl)methanone 100 MHz, CDCl3

164.39	51.55 48.53 45.71	138.72	130.03 129.42	121.99	11.11
Ī	ΠŢ	Ī	$\langle \rangle$	Ī	Ī






















 $(1H-pyrazol-1-yl)((3aR,5S,5aR,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl) methanone 100\ MHz,\ CDCl3$













¹⁹F NMR Spectra of Synthesized Compounds

(4-fluorophenyl)(1H-pyrazol-1-yl)methanone 377 MHz, CDCl3





-107.8 -107.9 -108.0 ppm





0

(1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone 377 MHz, CDCl3



(2-bromo-4-fluorophenyl)(1H-pyrazol-1-yl)methanone 377 MHz, CDCl3



62 60 23 28 21